Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom May Launch Gene-Expression Service This Year; Genotyping Service to Follow

SALT LAKE CITY, Oct. 31 (GenomeWeb News) - After launching its DNA-methylation-analysis service last week, Sequenom will likely launch a gene-expression service within the year, and launch a genotyping service later, company officials told GenomeWeb News last week.

 

Sequenom is currently taking the first orders for its expression service, so "one could argue that it's being launched now," said Christian Jurinke, the company's director of product development. He spoke with GenomeWeb News during the American Society for Human Genetics meeting, held here last week.

 

The expression service will likely officially launch before the end of the year, with a genotyping service launch to follow soon after, said Jurinke. He declined to provide a more specific timeline.

 

The two new services have the potential to complement the company's new DNA-methylation service, but they will not be explicitly linked in any way in the near future, said Jurinke.

 

As GenomeWeb News reported, Sequenom launched its methylation detection service last Wednesday. The company provided preview versions of its upcoming DNA-methylation-detection software product for the MassArray platform to four investigators, Jurinke said.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.